SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today unveiled the ...
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients ...
The project focuses on developing automated workflows for minimally invasive neurovascular and tumor treatments – clinical procedures where staffing levels and specialized expertise are in short ...
QEL-001 Phenotype-Locked™ CAR-Tregs remained detectable in the circulation for over 1 year post-dose, maintaining a stable, highly suppressive Treg phenotype characterized by expression of key ...
SNIPR also provided a clinical update on its ongoing Phase 1b trial of SNIPR001 in patients with hematological cancer undergoing hematopoietic stem-cell transplantation (HSCT). Recruitment in this ...
Rapid results for ADHD, Anxiety and OCD: Improves executive function and lessens the din of unwelcome thoughts. Calms the overactive amygdala to assist patients in processing trauma free of physical ...
Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was ...
Peters brings over 15 years of senior care and financial expertise to advance Care@Home 4 Life's mission of keeping seniors safely in the homes they love. Miami, FL, March 02, 2026 (GLOBE NEWSWIRE) -- ...
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its ...
J.P. Morgan is acting as the underwriter for the offering.
Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility own ...
Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results